After bariatric surgery , thromboembolics complications are major cause of mortality. However, in obese patients, thromboprophylaxia is a controversy. Fondaparinux' efficacy is superior to HBPM, and is a good treatment for this population. Pharmacokinetics information with Fondaparinux in this population are rare.
We proposed a bicentric study cohort of obese patients (BMI \> 40 kg/m2) treated by 1 day injection of Fondaparinux 2.5 mg after bypass surgery. Anti-Xa activity of Fondaparinux will be measured 4 times during hospitalisation for each patient to realise a pharmacokinetic modelisation of Fondaparinux. Haemorrhage and thromboembolics events will be collected.
Study Type
OBSERVATIONAL
Enrollment
40
patients with a fondaparinux treatment who have 4 blood samples during the 10 days following surgery
Assistance Publique - Hôpitaux de Paris
Paris, France
Clinique de la Mutualiste
Saint-Etienne, France
Chu de Saint-Etienne
Saint-Etienne, France
To evaluate pharmacodynamics parameters of fondaparinux based on anti-Xa activity estimated by a non linear model at mixed effect of obese morbid patients following a bariatric surgery
Time frame: 5 days
To evaluate the incidence of symptomatic venous thromboembolics events (DVT and PE) between D5 and D10 and at 1month ± 10 days
Time frame: D5
the incidence of major and clinically significative bleeding between D5 and D10 and at 1 month ± 10 days
Time frame: 5 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.